See more : Alpha Purchase Co., Ltd. (7115.T) Income Statement Analysis – Financial Results
Complete financial analysis of Otonomy, Inc. (OTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Otonomy, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Lippo Malls Indonesia Retail Trust (LPMDF) Income Statement Analysis – Financial Results
- WAC Holdings Limited (8619.HK) Income Statement Analysis – Financial Results
- Spring Valley Acquisition Corp. II (SVIIW) Income Statement Analysis – Financial Results
- Tortoise Midstream Energy Fund, Inc. (NTG) Income Statement Analysis – Financial Results
- GGL Resources Corp. (GGLXF) Income Statement Analysis – Financial Results
Otonomy, Inc. (OTIC)
About Otonomy, Inc.
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.00K | 273.00K | 600.00K | 745.00K | 1.24M | 683.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 370.00K | 1.19M | 912.00K | 946.00K | 3.10M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -245.00K | -915.00K | -312.00K | -201.00K | -1.86M | -981.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -196.00% | -335.16% | -52.00% | -26.98% | -150.65% | -143.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 34.67M | 28.00M | 32.81M | 31.84M | 42.70M | 60.72M | 38.76M | 31.80M | 16.34M | 8.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.71M | 14.58M | 11.69M | 20.01M | 46.84M | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Other Expenses | 0.00 | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | -14.00K | 3.71M |
| Operating Expenses | 49.38M | 42.57M | 44.50M | 51.85M | 89.54M | 110.50M | 61.98M | 39.64M | 19.85M | 10.93M |
| Cost & Expenses | 49.75M | 43.76M | 45.41M | 52.80M | 92.64M | 112.16M | 61.98M | 39.64M | 19.85M | 10.93M |
| Interest Income | 43.00K | 326.00K | 1.72M | 1.69M | 1.27M | 899.00K | 419.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.60M | 1.57M | 1.59M | 4.00K | 0.00 | 0.00 | 0.00 | 39.00K | 2.53M | 444.00K |
| Depreciation & Amortization | 856.00K | 1.06M | 1.15M | 1.19M | 1.29M | 708.00K | 358.00K | 213.00K | 257.00K | 192.00K |
| EBITDA | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.61M | -7.03M |
| EBITDA Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.85M | -10.93M |
| Operating Income Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.56M | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | 291.00K | 3.36M |
| Income Before Tax | -51.18M | -44.73M | -44.68M | -50.37M | -90.13M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Income Before Tax Ratio | -40,944.80% | -16,384.98% | -7,445.83% | -6,760.81% | -7,292.07% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -856.00K | -1.06M | -1.15M | -1.19M | -1.29M | -708.00K | -358.00K | -213.00K | 2.51M | 4.15M |
| Net Income | -50.33M | -43.67M | -43.53M | -49.18M | -88.84M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Net Income Ratio | -40,260.00% | -15,995.97% | -7,254.33% | -6,601.61% | -7,187.78% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| EPS Diluted | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| Weighted Avg Shares Out | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
| Weighted Avg Shares Out (Dil) | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
Why Is Otonomy (OTIC) Stock Up 97% Today?
Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
Otonomy, Inc. (OTIC) CEO Dave Weber on Q2 2022 Results - Earnings Call Transcript
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Otonomy, Inc. (OTIC) CEO Dr. David Weber on Q1 2022 Results - Earnings Call Transcript
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
Otonomy: Hearing Loss And Tinnitus Data In 2022
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
Source: https://incomestatements.info
Category: Stock Reports